 Navin Fluorine International Ltd approves capex
Navin Fluorine International Ltd approves capex Purest gold, silver products in 10 minutes: MMTC-PAMP partners with Swiggy Instamart
Purest gold, silver products in 10 minutes: MMTC-PAMP partners with Swiggy Instamart Cosmo Plastech Expands Rigid Packaging Solutions for the Pharmaceutical Industry with PET Sheets
Cosmo Plastech Expands Rigid Packaging Solutions for the Pharmaceutical Industry with PET Sheets IPO Note - Lenskart Solutions Ltd - Reliance Securities
IPO Note - Lenskart Solutions Ltd - Reliance Securities IndiGo expands its Middle East footprint with new Bengaluru-Riyadh direct flights, starting 16 November 2025
IndiGo expands its Middle East footprint with new Bengaluru-Riyadh direct flights, starting 16 November 2025 
              Q4FY21 topline remained subdued with growth in India and Germany offset by decline in US sales. Revenues stayed flattish, down 0.5% YoY to Rs. 1937 crore mainly due to 30.1% YoY decline in US formulations to Rs. 269 crore. Domestic sales grew 9.8% YoY to Rs. 922 crore. Brazil de-grew 3.6% YoY to Rs. 189 crore. Germany business grew a robust 23.6% YoY to Rs. 267 crore. EBITDA margins expanded 189 bps YoY to 30.0% mainly led by better gross margin performance. Subsequently, EBITDA grew 6.2% YoY to Rs. 582 crore. PAT grew 3.2% YoY to Rs. 324 crore. Delta vis-à-vis EBITDA was due to higher other income and lower interest cost being offset by negative tax (one-off) in base year.
For details, click on the link below: Link to the report
Shares of TORRENT PHARMACEUTICALS LTD. was last trading in BSE at Rs.2752.65 as compared to the previous close of Rs. 2723.4. The total number of shares traded during the day was 95247 in over 10074 trades.
The stock hit an intraday high of Rs. 2891.55 and intraday low of 2675.5. The net turnover during the day was Rs. 268371919.